Revon Systems Awarded National Science Foundation Small Business Technology Transfer Grant For Development Work on Digital Therapeutics

Grant will support development and commercialization of novel machine-learning backed triage applications for patients with Chronic Obstructive Pulmonary Disease


Louisville, KY: Digital therapeutics company, Revon Systems, has been awarded federal funding for the development of standalone mobile applications that detect declines in patient health early and guide the patient to the right level of care.

Revon Systems’ Chief Data Scientist, Dr. Sumanth Swaminathan, said, “Revon is thrilled that the National Science Foundation is supporting this vital technology development effort. COPD patients face a constant burden of symptom escalations, which lead to long-term decline in lung function and overall health. Thus far, observational studies of Revon’s respiratory therapeutics are showing a positive impact of the machine-learning backed triage applications on patient symptom severity, anxiety, and quality of life. The next crucial step is to optimize and validate the product for broader use by the respiratory patients around the globe.

“The National Science Foundation supports small businesses with the most innovative, cutting-edge ideas that have the potential to become great commercial successes and make huge societal impacts,” said Barry Johnson, Director of the NSF’s Division of Industrial Innovation and Partnerships. “We hope that this seed funding will spark solutions to some of the most important challenges of our time across all areas of science and technology.”

The NSF STTR Phase I award brings $225,000 into Revon’s product development effort.  Phase I work will focus on prototyping of the COPD Smart Symptom Tracker mobile application for optimization of patient adoption, retention, ease-of-use, and overall health. Phase II work, if awarded, will focus on complete commercialization of the validated product.

About Revon Systems: REVON is a digital therapeutics company that specializes in helping patients with cardiovascular and lung conditions to self-manage signs and symptoms, intervene early on health declines, and improve quality of life. REVON’s primary differentiating technology is a built-in machine learning feature called a Smart Symptom Tracker that interprets troubling symptoms and signs with the goal of finding the right level of care early.

About The NSF’s Small business Program: America’s Seed Fund powered by NSF awards $200 million annually to startups and small businesses, transforming scientific discovery into products and services with commercial and societal impact. Startups working across almost all areas of science and technology can receive up to $1.5 million in non-dilutive funds to support research and development (R&D), helping de-risk technology for commercial success. America’s Seed Fund is congressionally mandated through the Small Business Innovation Research (SBIR) program. The NSF is an independent federal agency with a budget of about $7.8 billion that supports fundamental research and education across all fields of science and engineering. For more information, visit

Revon Systems’ Digital Therapeutics Enters Collaboration with AstraZeneca in Respiratory Medicine

Revon’s Mobile Software Platform and Triage Algorithms will help to further evaluate new asthma trial endpoint

Louisville, KY: Digital therapeutics company, Revon Systems will be working with AstraZeneca’s Innovative Medicine and Early Development (IMED) Biotech Unit in respiratory clinical trials to evaluate CompEx, a novel therapeutic endpoint for asthma. CompEx is an algorithm combining patient-recorded lung function deterioration, symptoms and use of reliever medication with the traditional measurement of severe exacerbations.

Dr. Sumanth Swaminathan, Chief Data Scientist, Revon Systems said, “This is a great opportunity for Revon to leverage its triage algorithms and clinical trials platform in a respiratory trial. AstraZeneca has an exciting pipeline of investigational asthma therapies, and we are delighted to be partnering with them in this effort to transform asthma exacerbation trials.”

Dr. Carla A Da Silva, Director of Clinical Research, AstraZeneca said, “By using Revon’s technology we are able to conduct real-time assessments of CompEx events. We are eager to evaluate how these correlate with patient health escalations, medication usage, and Revon’s machine-learned triage prediction.”

In this collaboration, AstraZeneca’s clinical trial infrastructure will integrate with Revon’s Smart Symptom Trackers to help accelerate the development of novel respiratory therapies in clinical trials. Initially, Revon will provide its software platform and conduct real-time data analysis for one trial in Phase 2. Revon will also provide device support and training for enrolling patients onto the platform.

About Revon Systems: REVON is a digital therapeutics company that enables patients to self-manage their asthma and COPD signs and symptoms. REVON has a built-in machine learning feature called a Smart Symptom Tracker that helps patients interpret troubling symptoms and signs with the goal of finding the right level of care earlier in their illness.

Revon Systems Working with Oxford University to Build Next Generation Clinical Algorithms

Program will pair Oxford University mathematics doctoral students with Revon Systems data scientists developing algorithms for digital therapies.

LOUISVILLE, Ky., Sept. 7, 2017 /PRNewswire/ — Digital therapeutics company, Revon Systems, is teaming up with Oxford University’s program in Industrially Focused Mathematical Modeling (InFoMM) to bring the latest methods in machine-learning, predictive modeling, and decision science to bear on Revon’s digital therapies.

Revon Systems’ Chief Data Scientist, Dr. Sumanth Swaminathan, said, “We are thrilled to have the brightest global scientific minds on-board to do collaborative research on digital treatments of chronic illness.  Revon’s strategy for building digital therapies relies on timely and accurate algorithmic decision-support customized to patients.  The complexity of personalized solutions is high, and we are excited to explore the frontiers of our technology with the support of Oxford University’s top minds.”  Chris Breward, Director of the InFoMM Center for Doctoral Training (CDT) said, “Revons’ push to leverage cutting-edge modeling and machine learning techniques to reduce adverse health events in patients with chronic illnesses provides an exciting opportunity for Oxford’s faculty and students to collaborate on important medical problems.”

This new partnership combines expertise in quantitative methods and clinical science among academic researchers and product focused industrial practitioners.  Revon will provide resource support, data, and existing scientific knowledge in algorithmic triage.  Revon will also provide device and prototyping support to rapidly test and execute potential solutions that emerge from the partnership.  The InFoMM CDT will provide graduate student interns and faculty consultation on novel modeling and data analytics methods and contribute refereed publication level analysis and presentation of findings.

About Revon Systems: REVON is a digital therapeutics company that enables patients to self-track their COPD signs and symptoms. REVON has a built-in machine learning feature called a Smart Symptom Tracker that helps patients interpret troubling symptoms and signs with the goal of finding the right level of care earlier in their illness.

About Oxford University InFoMM CDT: The InFoMM CDT is a partnership between The United Kingdom’s Engineering and Physical Sciences Research Council (EPSRC), the University of Oxford, and a large number of industry partners.  Research focus of the center includes quantitative methods in the fields of: data analytics, differential equations, asymptotic methods, numerical analysis, scientific computing, fluid and solid mechanics, discrete mathematics, and applied mathematical finance.

Revon Systems Powers Real World Evidence Mobile Platform for Rare Disease Study managed by ClinTec International

LOUISVILLE, Ky., Sept. 6, 2017 /PRNewswire/ — Revon Systems Inc. announced today that it will support ClinTec International as the symptom tracking technology provider for a year long real world natural history study in the United Kingdom for patients diagnosed with a very rare blood disease.

The Revon Systems platform (REVON) will securely collect patient symptom surveys and patient activity data. Patients will report their symptoms using REVON’s software from their smartphones and integrated Misfit activity trackers. The platform also offers robust support for physician reported outcomes from office visits.

Dr. Ted Smith, CEO of Revon Systems said, “We are excited to support such important rare disease research with a world-class biotech clinical research organization. This rare disease study is the perfect project for REVON because of their need for both patient and physician secure data capture on the smartphone or during the office visit.”

Dr. Rabinder Buttar, Founder and CEO of ClinTec, said: “Our goal is to help our biotech clients meet their research needs and Revon Systems adds that real world data dimension to this natural history study with their ability to handle patient and physician reported clinical outcomes with Bluetooth connected devices.” 

About Revon Systems: REVON is a digital health platform that enables patients to self-track their chronic disease signs and symptoms, and communicate more effectively with their healthcare providers. In addition to symptom tracking, REVON is pursuing a therapeutic version of the platform using a machine learning feature that helps patients with certain respiratory conditions make more informed care seeking decisions.

About ClinTec International  ClinTec International is a global full service Contract Research Organization (CRO) with an organically grown presence, including legal entities, in over 50 developed and emerging countries and with operational capabilities in more than 80 countries. ClinTec provides innovative full and functional clinical research solutions to 7 of the top 10 pharmaceutical companies in the world, as well as leading biotechnology and medical device firms in oncology, rare diseases and other therapeutic areas. In addition, ClinTec provides support to a diverse range of organizations, including not-for-profit organizations, to develop medicines for infectious diseases in countries where significant unmet needs exist.

Breathe Easier: New Smartphone App Could Help COPD Patients

By Lisa Gillespie (

July 28, 2017: Kentucky has the nation’s highest rate of people with chronic obstructive pulmonary disease, or COPD. But managing the disease and interpreting symptoms is often a challenge for people who suffer from the lung disease.

Enter a new smartphone app that aims to use technology to help COPD sufferers to recognize emergencies, and avoid unnecessary doctors’ or ER visits. The app made its debut earlier today, screening people at the Family Community Clinic in Butchertown.

One of the first testers was Barry. When he walked through the door at the clinic, he had already been diagnosed with COPD. We’re only using his first name to protect his privacy.

Barry is 62-years-old. He said he started smoking at age 25, and later took a job in Rubbertown making paper bags where he inhaled chemicals daily. He blames the combination of smoking and industrial work for his health problems.

“Working with chemicals, breathing it in, yea, you get [COPD],” Barry said.

All that exposure has caused Barry’s lungs to slowly harden and tighten. Sometimes, it’s very hard for him to breathe, especially on certain days.

“Days like this: rainy days, cloudy days, hot days [are not good], but a good sunny day, you’ll be all right,” Barry said.

A Chronic Problem For Kentuckians

COPD is prevalent in Kentucky. In 2011, almost ten percent of people in the commonwealth had COPD – the highest rate in the nation, followed by Alabama. And in 2015, almost a quarter of Kentuckians with COPD reported visiting the emergency room because of that condition and related emphysema.

Ted Smith is the CEO of Revon Systems, a tech company based in East Louisville, and the developer of the “Smart COPD” app. The app is designed on a simple premise: that some of those emergency room visits could have been prevented if people were able to track their symptoms.

“The focus of the app is helping you keep track of whether your systems are starting to deteriorate so that you don’t have to get to a point where you have to go to the hospital for emergency care” Smith said.

When you open the app, it poses a series of questions: “Shortness of breath?” “Cough?” and “Running nose or feeling like you have a cold?” It also asks for temperature, and for users to punch in the readings from a separate device that measures oxygen saturation and heart rate.

Finally, the app evaluates the information and tells the user whether they need to head to the ER, call their doctor, check back in a few days or that no medical attention is needed.

It’s simple, and requires only a cell phone and a cheap finger oxygen and heart rate monitor.

‘Not designer technology for rich people’

Family Community Clinic Executive Director Becky Montague said she can see the app working for her patients. The clinic is one of the only places in the region that doesn’t charge anything for medical care, so they end up caring for the approximately 80,000 people in the Louisville Metro Area that don’t have health insurance. She said the majority of her patients have a cell phone.

“People have telephones, they’re our life line. So putting a self-management tool on a cell phone is just a genius idea,” Montague said.

Smith said the clinic’s patients are the ones he wants to reach the most.

“The majority of digital health technologies have been created for those that are commercially insured, typically these are expensive,” Smith said. “[Smart COPD] is not designer technology for rich people, it’s good technology for everybody.”

Barry–like many low-income Americans–has a cell phone obtained through Medicaid. Smith said these phones don’t come with health-related apps already downloaded, but they could. He sees that as a possible opportunity for Smart COPD to reach more people with low-incomes.

“If there’s one thing I wish for, it’s that we take advantage of something we’re already paying for as a society and turn it into health care,” Smith said.

On Friday, six people were screened at the Family Community Clinic. They’ll be part of a pilot study, and the clinic will follow up with them to measure the outcome of using the Smart COPD app.

Barry, in the meantime, manages with a daily inhaler and routine check-ups at the clinic. He’s interested in the Smart COPD app, and he left the clinic with information on how to use and download it. His cell phone doesn’t work very well, but even so, he has access to people who can download the app if he needs it.

“That’s where my nieces come in,” Barry said. “They got smart phones and if I need information, they can pull it up for me.”

Interested? Search for ‘Revon Systems’ in your App store and look for the “Smart COPD” app.


Original Story:

Revon Systems and Family Community Clinic partner to raise awareness of COPD

Revon Systems and Family Community Clinic will partner on Friday July 28th to raise
awareness on proper diagnosis of COPD with the promise of mobile-phone-based artificial intelligence for ongoing management of the disease.

Louisville, KY: Local digital therapeutics company, Revon Systems, along with the Kentucky chapter of the American Lung Association are teaming up with a volunteer local expert pulmonologist to hold an initial COPD screening day at the Family Community Clinic of Butchertown on July 28. Screenings are being offered free of cost to current clinic patients, all of whom are uninsured or underinsured.

Revon Systems CEO, Dr. Ted Smith, said, “We are excited to offer our mobile phone-based health tools to members of the community who do not have access to regular healthcare. The promise of machine learning and AI is likely to be greatest for those who have fewer resources – now, even the most basic Android mobile phone can help your manage your COPD symptoms for free.” Becky Montague, Director of the Family Community Clinic, said “We are excited to expand the care we provide to include expert pulmonologist who compassionately volunteer their time to help us screen for these serious lung disorders. We are also interested in exploring how our clinic can help patients at home who are uncertain about their breathing symptoms and signs with the Revon App.”

This new partnership combines lung function screening for current patients of the clinic and the Revon COPD app for Android and iPhone . Diagnosis is the first step to managing the disease and improving daily quality of life. Revon will also provide pulse oximeters and thermometers to be used with the COPD app while the American Lung Association will provide each patient with a packet of lung health education. The project was also made possible by the generosity of Norton Healthcare through the lending of diagnostic equipment. This Louisville Health Advisory Board project is also aligned with the Humana Bold Goal community-wide effort to increase the number of Healthy Days.

About Revon Systems: REVON is a digital therapeutics company that enables patients to selftrack their COPD signs and symptoms. REVON has a built-in machine learning feature called a Smart Symptom Tracker that helps patients interpret troubling symptoms and signs with the goal of helping patient get to the right level of care earlier in their illness.

About Family Community Clinic: Family Community Clinic is a non-profit, free clinic that is registered as a Charitable Health Provider in Kentucky. Services are provided by volunteer physicians, nurse practitioners, nurses, and other health professionals to adults & children without health insurance for acute, episodic illnesses. Interpreters are available for Spanish speakers. The facility is run on generous donations and grants from private, family foundations and individual contributions. Donations to the Family Community Clinic are fully tax deductible.

Louisville company makes a big move in deal with Cincinnati company

Revon Systems Inc. has reached an agreement with a Cincinnati-area pharmacy benefits management company, which will help the Louisville startup bring its health care technology platform to the market.

Revon will work with Appro-RX of Waynesville, Ohio, to use the technology it has been developing this year to provide a new kind of pharmacy benefit that uses technology to monitor medication patterns.

Revon is a digital health platform that helps patients track their chronic obstructive pulmonary disease (COPD) signs and symptoms, learn more about their condition and better communicate with health care professionals. The platform also allows health care professionals to easily view patients’ health data reported through the app or website.

Under the agreement, Appro-RX clients — mostly employers — will offer the Revon platform to their employees.

The agreement offers employers who use Appro-RX pharmacy services four main benefits, according to a news release:

  • The Revon COPD mobile app (for Android and iPhone) with the Smart Symptom Tracker;
  • The Breathe COPD Resource Kit with Bluetooth-connected pulse oximeter;
  • The Amazon Alexa Echo COPD skill, which helps patients triage their day-to-day symptoms;
  • Smart Formulary Services that combine medication adherence with Revon application use.

Revon CEO Ted Smith said in an interview that the agreement between the two companies will allow both to have access to the others’ data, creating a better relationship between employers, patients and the health care professionals involved in treating them.

He said he thinks that the two companies are the first to use technology to collect data to improve patient care in this manner. This surprises him because companies spend so much on prescription medications. Most employers pay these expenses without expecting better alignment between health care expenditures and outcomes, he said.

“This is the first of its kind, that I’m aware of, where we can get together to team up with insights and feedback to help people stay well,” he said. “Now (pharmacists) can go through and use that data. They can make a plan or benefit that actually works better for the customer.”

Originally published in Louisville Business First

EXCLUSIVE: Why your next prescription could be for an app

When your doctor writes you a prescription, you go to the pharmacy. But what if you could go to the App Store?

That’s the goal for Crestwood’s Revon Systems Inc., which hopes to one-day market its Smart COPD app as a sort of prescribable “digital therapeutic” for managing chronic obstructive pulmonary disease.

CEO Dr. Jeroen Schouten said in an interview that “there’s a lot of potential” for that revenue model — but there are also a lot of hoops to jump through first. The company will need to prove the app actually works, get approval by the U.S. Food and Drug Administration and apply to make it reimburseable by insurance.

The SmartCOPD app works by having users input their medical information and answer basic questions on their current symptoms, such as shortness of breath. Then the app tells them whether they’re fine, should call their doctor for a second opinion or that a flare-up is imminent and they should head straight to a hospital.

Schouten originally had planned to monetize the app through partnerships with researchers from the worlds of academics and commercial pharmaceutical and medical device development. The app could match eligible patients to the partners’ clinical trials.

That’s still a possibility, but “at some stage, we would have to make the revenue model work,” he said. “Every digital health care company is looking at how to make a revenue model that works.”

But the prescription model looks promising, since it’s already has worked for other health application companies. Schouten points to WellDoc, whose prescribeable app helps doctors and patients manage Type II diabetes.

If the prescription model pans out, patients could download the free app, and get a code from their doctor to unlock prescribed add-ons — sort of like an in-app purchase.

But, again, Revon needs to make sure the app works — both in terms of user design and in actually helping people effectively manage their chronic conditions.

“You’ve got to really know the market,” Schouten said. “You’ve got to really know how it works.”

Originally published in Louisville Business First